<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>The Evolution of Prostate Cancer: A Prognostic Infographic</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Roboto+Condensed:wght@400;700&family=Roboto:wght@400;500;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --stage-1-color: #7dd3fc; /* sky-300 */
            --stage-2-color: #67e8f9; /* cyan-300 */
            --stage-3-color: #fca5a5; /* red-300 */
            --stage-4-color: #f87171; /* red-400 */
            --stage-5-color: #ef4444; /* red-500 */
            --stage-6-color: #b91c1c; /* red-700 */
            --intervention-color: #64748b; /* slate-500 */
        }

        body {
            font-family: 'Roboto', sans-serif;
            background-color: #f8fafc;
            color: #334155;
            -webkit-print-color-adjust: exact;
        }

        .infographic-container {
            width: 100%;
            max-width: 1600px;
            margin: 2rem auto;
            padding: 2rem;
            position: relative;
        }

        h1, h2, h3 {
            font-family: 'Roboto Condensed', sans-serif;
            font-weight: 700;
            color: #1e293b;
        }
        
        /* Main grid layout for each stage row */
        .stage-row-grid {
            display: grid;
            grid-template-columns: 2fr 1fr 9fr;
            gap: 1.5rem;
            align-items: stretch; /* Ensures all items in a row have the same height */
        }
        
        /* Timeline Cell Styling */
        .timeline-cell {
            position: relative;
            display: flex;
            justify-content: center;
            align-items: center;
        }

        /* Vertical line segments for the timeline */
        .timeline-cell::before, .timeline-cell::after {
            content: '';
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 4px;
            background: #d1d5db;
            z-index: 1;
        }
        .timeline-cell::before { /* Top segment */
            top: 0;
            bottom: 50%;
            margin-bottom: 12px; /* half dot size */
        }
        .timeline-cell::after { /* Bottom segment */
            top: 50%;
            bottom: 0;
            margin-top: 12px; /* half dot size */
        }
        
        /* Hide ends of the timeline */
        .stage-row:first-child .timeline-cell::before { display: none; }
        .stage-row:last-child .timeline-cell::after { display: none; }


        .timeline-dot {
            width: 24px;
            height: 24px;
            border-radius: 50%;
            border: 4px solid white;
            z-index: 2;
            position: relative;
            box-shadow: 0 0 0 4px;
        }

        /* Stage Styling */
        .stage-card {
            text-align: right;
            position: relative;
            display: flex;
            flex-direction: column;
            justify-content: center;
        }
        .stage-card h3 {
            font-size: 1.25rem;
            line-height: 1.3;
        }
        .stage-card p {
            font-size: 1rem;
            color: #64748b;
        }

        /* Findings Column Styling */
        .findings-grid {
            display: grid;
            grid-template-columns: repeat(5, 1fr);
            gap: 1rem;
        }

        .modality-header {
            text-align: center;
            font-size: 1rem;
            font-weight: 700;
            color: #475569;
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 0.5rem;
        }
        
        .finding-card {
            background-color: #ffffff;
            border-radius: 0.5rem;
            padding: 0.85rem;
            font-size: 0.95rem;
            line-height: 1.5;
            border-left: 4px solid;
            box-shadow: 0 1px 3px 0 rgb(0 0 0 / 0.1), 0 1px 2px -1px rgb(0 0 0 / 0.1);
        }
        
        /* Connector lines SVG */
        #connector-svg {
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            pointer-events: none;
            z-index: 0;
        }
        
        path.connector-line {
            stroke-width: 1.5px;
            fill: none;
            stroke: #cbd5e1;
        }
        
        /* Specific Stage Colors */
        .finding-card.stage-1-border { border-color: var(--stage-1-color); }
        .finding-card.stage-2-border { border-color: var(--stage-2-color); }
        .finding-card.stage-3-border { border-color: var(--stage-3-color); }
        .finding-card.stage-4-border { border-color: var(--stage-4-color); }
        .finding-card.stage-5-border { border-color: var(--stage-5-color); }
        .finding-card.stage-6-border { border-color: var(--stage-6-color); }

        /* Intervention Section Styling */
        .intervention-card {
            background-color: #f1f5f9;
            border-radius: 0.75rem;
            padding: 1.5rem;
            border-top: 4px solid var(--intervention-color);
        }
        .intervention-card h3 {
            font-size: 1.5rem;
            color: var(--intervention-color);
        }
         .intervention-card > p {
            color: #64748b;
            margin-bottom: 1.5rem;
            font-size: 1rem;
        }
        .findings-grid-intervention {
            display: grid;
            gap: 1.25rem;
        }
        .findings-grid-intervention h4 {
            font-weight: 700;
            color: #475569;
            margin-bottom: 0.25rem;
            font-size: 1rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }
        .findings-grid-intervention p {
             font-size: 0.95rem;
             line-height: 1.5;
        }
        
        @media print {
            body {
                background-color: #ffffff;
            }
            .infographic-container {
                margin: 0;
                padding: 1cm;
                box-shadow: none;
            }
            .finding-card, .intervention-card {
                box-shadow: none;
                border: 1px solid #e2e8f0;
            }
        }
    </style>
</head>
<body class="bg-slate-50">

    <div class="infographic-container">
        <svg id="connector-svg"></svg>
        
        <!-- Headers for the findings columns -->
        <div class="stage-row-grid mb-4">
            <div class="col-start-3">
                <div class="findings-grid">
                    <div class="modality-header">
                        <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 9a3 3 0 100-6 3 3 0 000 6zm-7 9a7 7 0 1114 0H3z" clip-rule="evenodd" /></svg>
                        Clinical & Lab
                    </div>
                    <div class="modality-header">
                        <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M5 3a2 2 0 00-2 2v2a2 2 0 002 2h2a2 2 0 002-2V5a2 2 0 00-2-2H5zM5 11a2 2 0 00-2 2v2a2 2 0 002 2h2a2 2 0 002-2v-2a2 2 0 00-2-2H5zM11 5a2 2 0 012-2h2a2 2 0 012 2v2a2 2 0 01-2 2h-2a2 2 0 01-2-2V5zM11 13a2 2 0 012-2h2a2 2 0 012 2v2a2 2 0 01-2 2h-2a2 2 0 01-2-2v-2z" /></svg>
                        CT
                    </div>
                    <div class="modality-header">
                        <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M11.3 1.046A1 1 0 0112 2v5h4a1 1 0 01.82 1.573l-7 10A1 1 0 018 18v-5H4a1 1 0 01-.82-1.573l7-10a1 1 0 011.12-.38z" clip-rule="evenodd" /></svg>
                        MRI
                    </div>
                    <div class="modality-header">
                        <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.05 3.636a1 1 0 011.414 0L10 7.172l3.536-3.536a1 1 0 111.414 1.414L11.414 8.586l3.536 3.536a1 1 0 11-1.414 1.414L10 9.999l-3.536 3.536a1 1 0 01-1.414-1.414L8.586 8.586 5.05 5.05a1 1 0 010-1.414z" clip-rule="evenodd" /></svg>
                        PSMA-PET
                    </div>
                    <div class="modality-header">
                        <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M15 4a3 3 0 11-6 0 3 3 0 016 0zM12 2a5 5 0 00-5 5c0 1.284.483 2.45 1.285 3.356L3.11 18.53A1.5 1.5 0 004.225 20h11.55a1.5 1.5 0 001.115-2.47l-5.175-8.174A4.978 4.978 0 0017 7a5 5 0 00-5-5z" /></svg>
                        Histopathology
                    </div>
                </div>
            </div>
        </div>

        <div class="stages-container space-y-8">
            <!-- STAGE 1 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-1" class="stage-card">
                    <h3>Risk Factors & Premalignant State</h3>
                    <p>Cellular changes driven by risk factors</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-sky-300" style="box-shadow: 0 0 0 4px var(--stage-1-color);"></div>
                </div>
                <div class="findings-grid">
                    <div id="stage-1-clinical" class="finding-card stage-1-border"><strong>Asymptomatic.</strong> Family history, age, ethnicity. Baseline PSA, risk calculators.</div>
                    <div id="stage-1-ct" class="finding-card stage-1-border">Cannot visualize tumor. Can quantify systemic risks: visceral fat, sarcopenia.</div>
                    <div id="stage-1-mri" class="finding-card stage-1-border">Not typically used for risk factors alone. May show benign changes (BPH).</div>
                    <div id="stage-1-pet" class="finding-card stage-1-border">Not indicated. No PSMA expression in precursor lesions.</div>
                    <div id="stage-1-path" class="finding-card stage-1-border">Biopsy may show precursor lesions like High-Grade PIN or ASAP.</div>
                </div>
            </div>
            <!-- STAGE 2 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-2" class="stage-card">
                     <h3>Organ-Confined Disease</h3>
                    <p>Early cancer (T1/T2) within the prostate capsule</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-cyan-300" style="box-shadow: 0 0 0 4px var(--stage-2-color);"></div>
                </div>
                <div class="findings-grid">
                    <div id="stage-2-clinical" class="finding-card stage-2-border"><strong>Asymptomatic.</strong> Elevated PSA is key. Post-RP, PSA should be undetectable.</div>
                    <div id="stage-2-ct" class="finding-card stage-2-border">Cannot visualize organ-confined tumors. No role in local staging.</div>
                    <div id="stage-2-mri" class="finding-card stage-2-border"><strong>Standard for detection.</strong> Shows tumor as low T2 signal, low ADC, and early enhancement.</div>
                    <div id="stage-2-pet" class="finding-card stage-2-border">Visualizes primary tumor. High SUVmax & PSMA-TV correlate with aggressiveness.</div>
                    <div id="stage-2-path" class="finding-card stage-2-border"><strong>Definitive diagnosis.</strong> Biopsy confirms adenocarcinoma & Gleason Score.</div>
                </div>
            </div>
            <!-- STAGE 3 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-3" class="stage-card">
                    <h3>Aggressive Histological Features</h3>
                    <p>Transition to high-grade disease</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-red-300" style="box-shadow: 0 0 0 4px var(--stage-3-color);"></div>
                </div>
                <div class="findings-grid">
                    <div id="stage-3-clinical" class="finding-card stage-3-border">No unique symptoms. Often higher PSA, rapid PSA kinetics (short PSADT).</div>
                    <div id="stage-3-ct" class="finding-card stage-3-border">Not directly visible. CT Perfusion may show increased angiogenesis (high Blood Flow).</div>
                    <div id="stage-3-mri" class="finding-card stage-3-border">Progressively lower ADC values. Radiomics can quantify heterogeneity linked to cribriform pattern.</div>
                    <div id="stage-3-pet" class="finding-card stage-3-border">High PSMA-TV on staging scans is predictive of cribriform pattern and LVI.</div>
                    <div id="stage-3-path" class="finding-card stage-3-border"><strong>Gold Standard.</strong> Direct visualization of cribriform architecture or IDC-P (Gleason Pattern 4).</div>
                </div>
            </div>
            <!-- STAGE 4 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-4" class="stage-card">
                    <h3>Local Invasion</h3>
                    <p>Extracapsular Extension (T3/T4)</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-red-400" style="box-shadow: 0 0 0 4px var(--stage-4-color);"></div>
                </div>
                <div class="findings-grid">
                    <div id="stage-4-clinical" class="finding-card stage-4-border">Onset of local urinary/erectile symptoms. Rising PSA, short PSADT.</div>
                    <div id="stage-4-ct" class="finding-card stage-4-border">Low sensitivity for microscopic ECE. Can depict gross extension (T3/T4) into fat/bladder.</div>
                    <div id="stage-4-mri" class="finding-card stage-4-border"><strong>Crucial for staging.</strong> Shows capsular disruption, SVI. Length of capsular contact assesses risk.</div>
                    <div id="stage-4-pet" class="finding-card stage-4-border">Can detect PSMA-avid tumor foci extending beyond the capsule, improving staging of ECE/SVI.</div>
                    <div id="stage-4-path" class="finding-card stage-4-border"><strong>Definitive diagnosis on RP.</strong> Microscopic confirmation of tumor beyond capsule (ECE) or in seminal vesicles (SVI).</div>
                </div>
            </div>
            <!-- STAGE 5 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-5" class="stage-card">
                    <h3>Regional Spread</h3>
                    <p>Lymph Node Metastasis (N1)</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-red-500" style="box-shadow: 0 0 0 4px var(--stage-5-color);"></div>
                </div>
                <div class="findings-grid">
                     <div id="stage-5-clinical" class="finding-card stage-5-border"><strong>Usually asymptomatic.</strong> Primary sign is Biochemical Recurrence (BCR) - rising PSA post-therapy.</div>
                    <div id="stage-5-ct" class="finding-card stage-5-border">Standard for N-staging but low sensitivity. Relies on node size (>1cm), missing micrometastases.</div>
                    <div id="stage-5-mri" class="finding-card stage-5-border">Better than CT. Detects suspicious nodes by size, shape, low ADC. Still limited for small nodes.</div>
                    <div id="stage-5-pet" class="finding-card stage-5-border"><strong>New Gold Standard.</strong> High accuracy for detecting small, metastatic nodes based on molecular signature, not size.</div>
                    <div id="stage-5-path" class="finding-card stage-5-border"><strong>Definitive confirmation.</strong> Histology of dissected nodes confirms number of positive nodes & extranodal extension (ENE).</div>
                </div>
            </div>
            <!-- STAGE 6 ROW -->
            <div class="stage-row stage-row-grid">
                <div id="stage-6" class="stage-card">
                     <h3>Distant Dissemination</h3>
                    <p>Bone Metastasis (M1b)</p>
                </div>
                <div class="timeline-cell">
                    <div class="timeline-dot bg-red-700" style="box-shadow: 0 0 0 4px var(--stage-6-color);"></div>
                </div>
                <div class="findings-grid">
                    <div id="stage-6-clinical" class="finding-card stage-6-border"><strong>Symptomatic.</strong> Bone pain is most common. Elevated AP, anemia. Detectable CTCs.</div>
                    <div id="stage-6-ct" class="finding-card stage-6-border"><strong>Excellent for visualization.</strong> Clearly shows high-density osteoblastic lesions and assesses fracture risk.</div>
                    <div id="stage-6-mri" class="finding-card stage-6-border"><strong>Highly sensitive for early detection.</strong> Shows replacement of bright fatty marrow with dark tumor signal.</div>
                    <div id="stage-6-pet" class="finding-card stage-6-border"><strong>Higher sensitivity than bone scan.</strong> Visualizes viable tumor cells and quantifies total metastatic burden.</div>
                    <div id="stage-6-path" class="finding-card stage-6-border">Bone biopsy confirms metastatic adenocarcinoma, but not always required if imaging is clear.</div>
                </div>
            </div>
        </div>

        <!-- INTERVENTION SECTION -->
        <div class="mt-16 pt-8 border-t-2 border-slate-200">
            <header class="text-center mb-8">
                <h2 class="text-3xl font-bold text-slate-800">Therapeutic Interventions Altering Disease Evolution</h2>
            </header>
            <div class="grid grid-cols-1 md:grid-cols-3 gap-8">
                <!-- Card for Radical Prostatectomy -->
                <div class="intervention-card">
                    <h3>Radical Prostatectomy</h3>
                    <p>Removes the primary tumor in localized disease to prevent spread and provide definitive staging.</p>
                    <div class="findings-grid-intervention">
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 9a3 3 0 100-6 3 3 0 000 6zm-7 9a7 7 0 1114 0H3z" clip-rule="evenodd" /></svg>
                                Clinical & Lab
                            </h4>
                            <p>Post-op PSA should become undetectable. A rising PSA (≥0.2 ng/ml) defines Biochemical Recurrence (BCR), the first sign of treatment failure.</p>
                        </div>
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M15 4a3 3 0 11-6 0 3 3 0 016 0zM12 2a5 5 0 00-5 5c0 1.284.483 2.45 1.285 3.356L3.11 18.53A1.5 1.5 0 004.225 20h11.55a1.5 1.5 0 001.115-2.47l-5.175-8.174A4.978 4.978 0 0017 7a5 5 0 00-5-5z" /></svg>
                                Histopathology
                            </h4>
                            <p><strong>Gold standard for prognosis.</strong> Provides definitive pathological stage (pT), Gleason Score, and confirms adverse features (ECE, SVI), margin status (PSM), and nodal status (pN).</p>
                        </div>
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3.172 5.172a4 4 0 015.656 0L10 6.343l1.172-1.171a4 4 0 115.656 5.656L10 17.657l-6.828-6.829a4 4 0 010-5.656z" clip-rule="evenodd" /></svg>
                                Functional Outcomes
                            </h4>
                            <p>Prognosis also defined by Quality of Life. High rates of erectile dysfunction and urinary incontinence can occur, which must be balanced against oncological benefits.</p>
                        </div>
                    </div>
                </div>
                <!-- Card for Hormonal Therapy -->
                <div class="intervention-card">
                    <h3>Hormonal Therapy (ADT)</h3>
                    <p>A systemic therapy for advanced disease that targets the androgen receptor (AR) signaling axis.</p>
                    <div class="findings-grid-intervention">
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 9a3 3 0 100-6 3 3 0 000 6zm-7 9a7 7 0 1114 0H3z" clip-rule="evenodd" /></svg>
                                Clinical & Lab
                            </h4>
                            <p>Leads to initial sharp decline in PSA. Long-term prognosis is linked to PSA nadir (lowest level) and time-to-nadir; a high nadir or short time predicts earlier resistance.</p>
                        </div>
                         <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M5 3a2 2 0 00-2 2v2a2 2 0 002 2h2a2 2 0 002-2V5a2 2 0 00-2-2H5zM5 11a2 2 0 00-2 2v2a2 2 0 002 2h2a2 2 0 002-2v-2a2 2 0 00-2-2H5zM11 5a2 2 0 012-2h2a2 2 0 012 2v2a2 2 0 01-2 2h-2a2 2 0 01-2-2V5zM11 13a2 2 0 012-2h2a2 2 0 012 2v2a2 2 0 01-2 2h-2a2 2 0 01-2-2v-2z" /></svg>
                                Imaging (CT/PET/MRI)
                            </h4>
                            <p>Causes body composition changes on CT (muscle loss, fat gain). PSMA-PET uptake decreases (but can flare initially). MRI can show reduced citrate, reflecting cell atrophy.</p>
                        </div>
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.707-10.293a1 1 0 00-1.414-1.414l-3 3a1 1 0 001.414 1.414L9 9.414V13a1 1 0 102 0V9.414l1.293 1.293a1 1 0 001.414-1.414l-3-3z" clip-rule="evenodd" /></svg>
                                Induced Evolution
                            </h4>
                            <p>Inevitably selects for resistance, leading to lethal Castration-Resistant PCa (CRPC) through AR-dependent or AR-independent (e.g., Neuroendocrine) pathways.</p>
                        </div>
                    </div>
                </div>
                 <!-- Card for Radioligand Therapy -->
                <div class="intervention-card">
                    <h3>Radioligand Therapy (RLT)</h3>
                    <p>A targeted approach for advanced mCRPC, delivering radiation directly to PSMA-positive cancer cells.</p>
                    <div class="findings-grid-intervention">
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M15.5 2.5a2.5 2.5 0 00-3.536 0L9.243 5.222a2.5 2.5 0 000 3.536l2.277 2.277a2.5 2.5 0 003.536 0l2.722-2.722a2.5 2.5 0 000-3.536L15.5 2.5zM12.723 9.243a.5.5 0 010-.707l2.277-2.277a.5.5 0 01.707 0l2.277 2.277a.5.5 0 010 .707L15.5 11.52a.5.5 0 01-.707 0l-2.07-2.07zM4.5 12.5a2.5 2.5 0 00-3.536 0L.5 12.964a2.5 2.5 0 000 3.536l2.036 2.036a2.5 2.5 0 003.536 0l.464-.464a2.5 2.5 0 000-3.536L4.5 12.5z" /></svg>
                                Mechanism of Action
                            </h4>
                            <p>Uses ligands (e.g., ¹⁷⁷Lu-PSMA-617) to deliver a radioactive isotope directly to tumor cells, causing targeted cell death with minimal collateral damage.</p>
                        </div>
                         <div>
                            <h4>
                               <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.05 3.636a1 1 0 011.414 0L10 7.172l3.536-3.536a1 1 0 111.414 1.414L11.414 8.586l3.536 3.536a1 1 0 11-1.414 1.414L10 9.999l-3.536 3.536a1 1 0 01-1.414-1.414L8.586 8.586 5.05 5.05a1 1 0 010-1.414z" clip-rule="evenodd" /></svg>
                                Imaging & Selection
                            </h4>
                            <p>PSMA-PET is essential to confirm high PSMA expression on tumors, identifying patients who are likely to respond to the therapy (a "theranostic" approach).</p>
                        </div>
                        <div>
                            <h4>
                                <svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5" viewBox="0 0 20 20" fill="currentColor"><path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z" /><path fill-rule="evenodd" d="M4 5a2 2 0 012-2 3 3 0 003 3h2a3 3 0 003-3 2 2 0 012 2v11a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3zm-3 4a1 1 0 100 2h.01a1 1 0 100-2H7zm3 0a1 1 0 100 2h3a1 1 0 100-2h-3z" clip-rule="evenodd" /></svg>
                                Prognostic Impact
                            </h4>
                            <p>Significantly prolongs survival and delays progression in heavily pre-treated mCRPC patients, altering the terminal course of the disease.</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function drawConnectingLines() {
            const svg = document.getElementById('connector-svg');
            const container = document.querySelector('.infographic-container');
            if (!svg || !container) return;

            svg.innerHTML = '';
            const containerRect = container.getBoundingClientRect();

            const connections = [
                { from: '#stage-1', to: '#stage-1-clinical' },
                { from: '#stage-2', to: '#stage-2-clinical' },
                { from: '#stage-3', to: '#stage-3-clinical' },
                { from: '#stage-4', to: '#stage-4-clinical' },
                { from: '#stage-5', to: '#stage-5-clinical' },
                { from: '#stage-6', to: '#stage-6-clinical' }
            ];

            connections.forEach(connection => {
                const fromEl = document.querySelector(connection.from);
                const toEl = document.querySelector(connection.to);
                if (!fromEl || !toEl) return;

                const fromRect = fromEl.getBoundingClientRect();
                const toRect = toEl.getBoundingClientRect();

                const startX = fromRect.right - containerRect.left;
                const startY = fromRect.top + fromRect.height / 2 - containerRect.top;
                const endX = toRect.left - containerRect.left;
                const endY = toRect.top + toRect.height / 2 - containerRect.top;
                
                const path = document.createElementNS('http://www.w3.org/2000/svg', 'path');
                const controlPointX1 = startX + (endX - startX) * 0.3;
                const controlPointX2 = startX + (endX - startX) * 0.7;
                const d = `M ${startX} ${startY} C ${controlPointX1} ${startY}, ${controlPointX2} ${endY}, ${endX} ${endY}`;
                
                path.setAttribute('d', d);
                path.setAttribute('class', 'connector-line');
                svg.appendChild(path);
            });
        }
        
        window.addEventListener('DOMContentLoaded', () => {
            setTimeout(drawConnectingLines, 100);
        });
        window.addEventListener('resize', drawConnectingLines);
    </script>
</body>
</html>

